Business Description
Genetic Analysis AS
ISIN : NO0010692130
Total Employee Number:
18Compare
Compare
Traded in other countries / regions
GEAN.Sweden8V8.Germany IPO Date
2021-10-28Description
Genetic Analysis AS is a research-driven diagnostic company dedicated to delivering diagnostic solutions to the growing human microbiota market. It is providing a CE-marked gut microbiota analysis for testing bacterial imbalance in IBS and IBD patients. Geographically, it operates in the USA, Europe, and the Rest of the world. Geographically, the company sells products in the USA, Europe, and the rest of the world. The majority of its revenue is generated from the USA. The GA-map technology platform and product portfolio are currently used across three main market segments: Clinical diagnostics, research (academic and industry), and Consumer Health.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 2.3 | |||||
Equity-to-Asset | 0.46 | |||||
Debt-to-Equity | 0.39 | |||||
Debt-to-EBITDA | -1.71 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 0.07 | |||||
Beneish M-Score | -3.9 | |||||
WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -17.3 | |||||
3-Year EBITDA Growth Rate | 54.7 | |||||
3-Year EPS without NRI Growth Rate | 45 | |||||
3-Year FCF Growth Rate | 60.9 | |||||
3-Year Book Growth Rate | -38.5 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 61.38 | |||||
9-Day RSI | 56.43 | |||||
14-Day RSI | 53.58 | |||||
3-1 Month Momentum % | -4.59 | |||||
6-1 Month Momentum % | -9.88 | |||||
12-1 Month Momentum % | -22.08 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.53 | |||||
Quick Ratio | 1.46 | |||||
Cash Ratio | 1.11 | |||||
Days Inventory | 46.9 | |||||
Days Sales Outstanding | 33.07 | |||||
Days Payable | 252.44 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -38.1 | |||||
Shareholder Yield % | -37.52 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 70.61 | |||||
Operating Margin % | -60.41 | |||||
Net Margin % | -62.95 | |||||
EBITDA Margin % | -28.09 | |||||
FCF Margin % | -42.88 | |||||
OCF Margin % | -7.53 | |||||
ROE % | -44.02 | |||||
ROA % | -23.94 | |||||
ROIC % | -34.66 | |||||
3-Year ROIIC % | 3820.17 | |||||
ROC (Joel Greenblatt) % | -236.35 | |||||
ROCE % | -30.41 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 2.51 | |||||
PB Ratio | 2.03 | |||||
EV-to-EBIT | -3.37 | |||||
EV-to-EBITDA | -6.72 | |||||
EV-to-Revenue | 1.89 | |||||
EV-to-Forward-Revenue | 0.66 | |||||
EV-to-FCF | -4.59 | |||||
Price-to-GF-Value | 1.08 | |||||
Earnings Yield (Greenblatt) % | -29.67 | |||||
FCF Yield % | -16.39 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Genetic Analysis AS Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 1.567 | ||
| EPS (TTM) (€) | -0.014 | ||
| Beta | 4.0722 | ||
| 3-Year Sharpe Ratio | 0.21 | ||
| 3-Year Sortino Ratio | 0.53 | ||
| Volatility % | 109.39 | ||
| 14-Day RSI | 53.58 | ||
| 14-Day ATR (€) | 0.003023 | ||
| 20-Day SMA (€) | 0.04022 | ||
| 12-1 Month Momentum % | -22.08 | ||
| 52-Week Range (€) | 0.035 - 0.082 | ||
| Shares Outstanding (Mil) | 69.09 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Genetic Analysis AS Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Genetic Analysis AS Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-26 | In 130 days | ||
| Second quarter earnings results for 2026 | 2026-08-28 | In 40 days | ||
| First quarter earnings results for 2026 | 2026-05-28 | 0.05 (+0.00%) | ||
| General meeting for 2026 | 2026-05-20 15:00 | 0.04 (+0.00%) | ||
| Annual report for 2025 | 2026-05-04 | 0.08 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-27 | 0.08 (+81.82%) | ||
| Third quarter earnings results for 2025 | 2025-11-27 | 0.05 (+0.00%) | ||
| Second quarter earnings results for 2025 | 2025-08-27 | 0.05 (+0.00%) | ||
| First quarter earnings results for 2025 | 2025-05-27 | 0.13 (+41.62%) | ||
| General meeting for 2025 | 2025-05-19 15:00 | 0.10 (+5.94%) |
Show
Entries
Genetic Analysis AS Frequently Asked Questions
What is Genetic Analysis AS(FRA:8V8)'s stock price today?
The current price of FRA:8V8 is €0.04. The 52 week high of FRA:8V8 is €0.08 and 52 week low is €0.04.
When is next earnings date of Genetic Analysis AS(FRA:8V8)?
The next earnings date of Genetic Analysis AS(FRA:8V8) is 2026-08-28.
Does Genetic Analysis AS(FRA:8V8) pay dividends? If so, how much?
Genetic Analysis AS(FRA:8V8) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Genetic Analysis AS
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers